A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)

Estado	**Tipo de Participantes**	**Rangos de Edad**
EC Finalizado	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase II	191
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Tiene resultados	No	Si
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Multicéntrico internacional	seguridad, eficacia, farmacocinética, farmacodinamica, farmacogenética	NO

Información

Identificador
2023-507276-53-00 (CTIS)

Cod. Protocolo
M16-109

Transicionado 2017-001398-17

Área terapéutica
Enfermedades [C] - Cáncer [C04]|

Enfermedad investigada
Myelofibrosis

Título Científico
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)

Justificación

No aportado

Objetivo Principal

Evaluate the effect of navitoclax alone or in combination with ruxolitinib on spleen volume

Variables de Evaluación Primaria

35% spleen volume reduction from baseline (SVR35) at Week 24 measured by MRI/CT.

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

To assess the effect of navitoclax alone or in combination with ruxolitinib on total symptom score (TSS) as assessed by the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0 diary
To evaluate the effect of navitoclax alone or in combination with ruxolitinib on bone marrow fibrosis
To determine the rate of anemia response associated with navitoclax alone or in combination with ruxolitinib
To describe the safety profile and PK profile observed with navitoclax alone or in combination with ruxolitinib

Variables de Evaluación Secundaria

The secondary endpoints are at least 50% reduction in total symptom score from baseline measured by MFSAF 4.0; anemia response; and change in grade of bone marrow fibrosis.

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Subjects 18 years of age Cohorts 1b and 3 only: Subject has at least 2 symptoms each with a score 3 or a total score of 12, as measured by the MFSAF v4.0 on at least 4 out of 7 days during screening prior to study drug dosing Subject has splenomegaly defined as spleen palpation measurement 5 cm below costal margin or spleen volume 450 cm3 as assessed by MRI/CT Subject must meet the laboratory parameters (adequate bone marrow, renal and hepatic function) as defined in the protocol. Subjects with documented diagnosis of Intermediate or High-risk Primary

myelofibrosis, post-polycythemia vera myelofibrosis or postessential thrombocythemia myelofibrosis Subjects classified as intermediate-2 or high-risk myelofibrosis, as defined by the Dynamic International Prognostic Scoring System (DIPSS) Subject must be ineligible due to age, comorbidities, or unfit for unrelated or unmatched donor transplantation or unwilling to undergo stem cell transplantation at time of study entry ECOG 0, 1, or 2 Cohort 1a only: Subject must have received ruxolitinib therapy for at least 12 weeks and be currently on a stable dose of 10 mg twice daily of ruxolitinib for 8 weeks prior to the 1st dose of navitoclax. Cohort 1b only: Subject must have received treatment with ruxolitinib for 24 weeks with lack of efficacy OR for < 24 weeks with documented disease progression while on ruxolitinib OR for 28 days with intolerance defined as new RBC transfusion requirement Cohort 2 only: Subject must have received prior treatment with JAK-2 inhibitor therapy for at least 12 weeks OR for 28 days complicated by development of red blood cell transfusion requirement (at least 2 units/month for 2 months) OR grade 3 adverse events of thrombocytopenia, anemia, hematoma and/or hemorrhage Cohort 3 only: Subject must not have received prior treatment with a JAK-2 or BET inhibitor

Criterios de Exclusión

Splenic irradiation within 6 months prior to screening, or prior splenectomy. Leukemic transformation (> 10% blasts in peripheral blood or bone marrow aspirate/biopsy). Prior therapy with a BH3 mimetic compound or stem cell transplantation.

Calendario

(Última actualización: 09/01/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
25/02/2020	27/05/2020	18/06/2020	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
15/10/2021	No aportado	No aportado	29/01/2025	30/01/2025

Promotor

AbbVie Deutschland GmbH & Co. KG Germany

Knollstrasse

Contact Person

Global Clinical Trials Helpdesk

+4961117201520

global-clinical-trials@abbvie.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital General Universitario Gregorio Marañón

C/ Doctor Esquerdo, 46 28007 Madrid

ceim.hgugm@salud.madrid.org

915867007

Centros

Cerrado (19/01/2022)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Fundación Clínica Universidad de Navarra (CUN)

No iniciado (15/07/2021)

HOSPITAL CLINIC DE BARCELONA

Barcelona

BARCELONA

Fundació Clínic per a la Recerca Biomèdica

Cerrado (04/07/2025)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON

Madrid

MADRID

Fundación para la Investigación Biomédica del Hospital General Universitario

Cerrado (17/03/2025)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

No iniciado (15/07/2021)

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

Oviedo

ASTURIAS

FINBA - Fundación para la Investigación y la Innovación

Cerrado (14/02/2022)

Hospital Universitario Regional De Malaga

Málaga

MÁLAGA

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

Cerrado (05/03/2025)

Hospital Universitario Virgen De La Victoria

Málaga

MÁLAGA

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

Cerrado (26/02/2025)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Fundación para la investigación biomédica

Cerrado (29/05/2025)

Institut Catala D'oncologia

Badalona

BARCELONA

Medicamentos

-

-

ORAL

Código ATC: L01EJ01 - RUXOLITINIB

Principios Activos: N/A

Experimental

Navitoclax

TABLET

ORAL

-

Principios Activos: N/A

Huérfano **Experimental**

Navitoclax

TABLET

ORAL

-

Principios Activos: N/A

Huérfano **Experimental**

Tiene resultados

A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)

State	**Type of participants**	**Age Ranges**
Finished CT	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase II	191
Results	**Low level of intervention**	**Rare disease**
Has results	No	Yes
Geographic coverage	**Areas of the study**	**Advanced therapy**
International multicenter	safety, effectiveness, pharmacokinetics, pharmacodynamics, pharmacogenetics	NO

Information

Identifier
2023-507276-53-00 (CTIS)

Protocol Code
M16-109

Transitioned 2017-001398-17

Therapeutic area
Diseases [C] - Cancer [C04]|

Investigated Disease
Myelofibrosis

Scientific Title
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis (REFINE)

Rationale

Not provided

Main Objective

Evaluate the effect of navitoclax alone or in combination with ruxolitinib on spleen volume

Primary Endpoints

35% spleen volume reduction from baseline (SVR35) at Week 24 measured by MRI/CT.

Temporary moments of secondary assessment

Not provided

Secondary Objective

To assess the effect of navitoclax alone or in combination with ruxolitinib on total symptom score (TSS) as assessed by the Myelofibrosis Symptom Assessment Form (MFSAF) version 4.0 diary
To evaluate the effect of navitoclax alone or in combination with ruxolitinib on bone marrow fibrosis
To determine the rate of anemia response associated with navitoclax alone or in combination with ruxolitinib
To describe the safety profile and PK profile observed with navitoclax alone or in combination with ruxolitinib

Secondary Endpoints

The secondary endpoints are at least 50% reduction in total symptom score from baseline measured by MFSAF 4.0; anemia response; and change in grade of bone marrow fibrosis.

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Subjects 18 years of age Cohorts 1b and 3 only: Subject has at least 2 symptoms each with a score 3 or a total score of 12, as measured by the MFSAF v4.0 on at least 4 out of 7 days during screening prior to study drug dosing Subject has splenomegaly defined as spleen palpation measurement 5 cm below costal margin or spleen volume 450 cm3 as assessed by MRI/CT Subject must meet the laboratory parameters (adequate bone marrow, renal and hepatic function) as defined in the protocol. Subjects with documented diagnosis of Intermediate or High-risk Primary

myelofibrosis, post-polycythemia vera myelofibrosis or postessential thrombocythemia myelofibrosis Subjects classified as intermediate-2 or high-risk myelofibrosis, as defined by the Dynamic International Prognostic Scoring System (DIPSS) Subject must be ineligible due to age, comorbidities, or unfit for unrelated or unmatched donor transplantation or unwilling to undergo stem cell transplantation at time of study entry ECOG 0, 1, or 2 Cohort 1a only: Subject must have received ruxolitinib therapy for at least 12 weeks and be currently on a stable dose of 10 mg twice daily of ruxolitinib for 8 weeks prior to the 1st dose of navitoclax. Cohort 1b only: Subject must have received treatment with ruxolitinib for 24 weeks with lack of efficacy OR for < 24 weeks with documented disease progression while on ruxolitinib OR for 28 days with intolerance defined as new RBC transfusion requirement Cohort 2 only: Subject must have received prior treatment with JAK-2 inhibitor therapy for at least 12 weeks OR for 28 days complicated by development of red blood cell transfusion requirement (at least 2 units/month for 2 months) OR grade 3 adverse events of thrombocytopenia, anemia, hematoma and/or hemorrhage Cohort 3 only: Subject must not have received prior treatment with a JAK-2 or BET inhibitor

Exclusion criteria

Splenic irradiation within 6 months prior to screening, or prior splenectomy. Leukemic transformation (> 10% blasts in peripheral blood or bone marrow aspirate/biopsy). Prior therapy with a BH3 mimetic compound or stem cell transplantation.

Calendar

(Last Update: 09/01/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
25/02/2020	27/05/2020	18/06/2020	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
15/10/2021	Not aported	Not aported	29/01/2025	30/01/2025

Sponsor

AbbVie Deutschland GmbH & Co. KG Germany

Knollstrasse

Contact Person

Global Clinical Trials Helpdesk

+4961117201520

global-clinical-trials@abbvie.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital General Universitario Gregorio Marañón

C/ Doctor Esquerdo, 46 28007 Madrid

ceim.hgugm@salud.madrid.org

915867007

Sites

Closed (19/01/2022)

CLINICA UNIVERSIDAD DE NAVARRA

Pamplona/Iruña

NAVARRA

Fundación Clínica Universidad de Navarra (CUN)

not initialized (15/07/2021)

HOSPITAL CLINIC DE BARCELONA

Barcelona

BARCELONA

Fundació Clínic per a la Recerca Biomèdica

Closed (04/07/2025)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON

Madrid

MADRID

Fundación para la Investigación Biomédica del Hospital General Universitario

Closed (17/03/2025)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

not initialized (15/07/2021)

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

Oviedo

ASTURIAS

FINBA - Fundación para la Investigación y la Innovación

Closed (14/02/2022)

Hospital Universitario Regional De Malaga

Málaga

MÁLAGA

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

Closed (05/03/2025)

Hospital Universitario Virgen De La Victoria

Málaga

MÁLAGA

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

Closed (26/02/2025)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Fundación para la investigación biomédica

Closed (29/05/2025)

Institut Catala D'oncologia

Badalona

BARCELONA

Medication

-

-

ORAL

ATC code: L01EJ01 - RUXOLITINIB

Active Principles: N/A

Experimental

Navitoclax

TABLET

ORAL

-

Active Principles: N/A

Orphan **Experimental**

Navitoclax

TABLET

ORAL

-

Active Principles: N/A

Orphan **Experimental**

Has results